Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor presented as a / for intravenous use. It replaces deficient factor IX in patients with Hemophilia B, enabling normal clot formation.\n\nGNH India supplies Immunine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Immunine is a recombinant coagulation factor used to manage disorders of the intrinsic clotting pathway, primarily Hemophilia B.\n\nHemophilia B: restores clotting ability by providing functional factor IX.\nPerioperative management in Hemophilia B: supplies adequate factor levels during surgery to prevent excessive bleeding.\nBleeding episodes in Hemophilia B: enables rapid hemostasis during spontaneous or trauma‑induced bleeds.

Immunine may be associated with adverse reactions following intravenous administration.\n\nCommon Side Effects:\n- Infusion‑related reactions such as chills, fever, or flushing.\n- Headache or mild nausea.\n- Arthralgia or joint discomfort.\n- Transient elevation of liver enzymes.\n\nSerious or Rare Side Effects:\n- Development of inhibitory antibodies against factor IX.\n- Anaphylactic or severe allergic reactions.\n- Thromboembolic events including deep vein thrombosis.\n- Potential transmission of viral pathogens despite purification processes.

When using Immunine, several precautions should be observed to ensure safety and efficacy.\n\nDose adjustment: tailor dosing based on individual factor IX activity levels and clinical response.\nMonitor for inhibitors: regularly test for anti‑factor IX antibodies during therapy.\nAvoid in patients with known hypersensitivity to human plasma proteins.\nUse with caution in individuals with cardiovascular disease or a history of thrombosis.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunine can interact with other agents that affect hemostasis or immune response.\n\nMajor Interactions (Avoid):\n- Concurrent use of other plasma‑derived factor IX products may increase inhibitor risk.\n- Administration with high‑dose immunoglobulins can reduce factor IX efficacy.\n\nModerate Interactions (Monitor Closely):\n- Anticoagulants such as warfarin or heparin may require closer coagulation monitoring.\n- Antifibrinolytic agents (e.g., tranexamic acid) may increase thrombotic risk when combined.\n- NSAIDs or aspirin can exacerbate bleeding if factor levels are insufficient.